Dual monoamine modulation for improved treatment of major depressive disorder / Pierre V. Tran en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 1 (Febrero) . - pp. 78-86 Título : Dual monoamine modulation for improved treatment of major depressive disorder Tipo de documento: texto impreso Autores: Pierre V. Tran, Autor ; Frank P. Bymaster, Autor ; Robert K. McNamara, Autor Fecha de publicación: 2023 Artículo en la página: pp. 78-86 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Inhibidores de la captación adrenérgica, Monoaminas biogénicas, Química cerebral, Trastorno depresivo mayor, Inhibidores de la captación de neurotransmisores. Resumen: The worldwide scope of depressive illness and lack of fully effective pharmacotherapy mandates significant improvements in treatment paradigms. Current antidepressant medications remain limited by poor efficacy, slow onset of action, and untoward side effects. While the introduction of serotoninspecific reuptake inhibitors (SSRIs) offered significant improvements in tolerability, no improvements in efficacy or speed of onset have been made relative to the traditional and poorly tolerated tricyclic antidepressants (TCA). Link: ./index.php?lvl=notice_display&id=31047 [artículo] Dual monoamine modulation for improved treatment of major depressive disorder [texto impreso] / Pierre V. Tran, Autor ; Frank P. Bymaster, Autor ; Robert K. McNamara, Autor . - 2023 . - pp. 78-86. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 1 (Febrero) . - pp. 78-86 Palabras clave: Inhibidores de la captación adrenérgica, Monoaminas biogénicas, Química cerebral, Trastorno depresivo mayor, Inhibidores de la captación de neurotransmisores. Resumen: The worldwide scope of depressive illness and lack of fully effective pharmacotherapy mandates significant improvements in treatment paradigms. Current antidepressant medications remain limited by poor efficacy, slow onset of action, and untoward side effects. While the introduction of serotoninspecific reuptake inhibitors (SSRIs) offered significant improvements in tolerability, no improvements in efficacy or speed of onset have been made relative to the traditional and poorly tolerated tricyclic antidepressants (TCA). Link: ./index.php?lvl=notice_display&id=31047

---

1 (1 - 1 / 1)